A Comparison of the Aldosterone‐blocking Agents Eplerenone and Spironolactone
Open Access
- 10 April 2008
- journal article
- research article
- Published by Wiley in Clinical Cardiology
- Vol. 31 (4), 153-158
- https://doi.org/10.1002/clc.20324
Abstract
Improved understanding of the adverse pharmacological properties of aldosterone has prompted investigation of the clinical benefits of blocking aldosterone at the receptor level. This article reviews the pharmacology, clinical efficacy, and tolerability of the two available blocking agents, spironolactone and eplerenone. A Medline search identified clinical studies assessing spironolactone and eplerenone. Priority was given to large, well‐controlled, clinical trials and comparative studies. Pharmacological differences between spironolactone and eplerenone include lower affinity of eplerenone for progesterone, androgen, and glucocorticoid receptors; more consistently demonstrated nongenomic properties for eplerenone; and the presence of long‐acting metabolites for spironolactone. Both agents effectively treat hypertension and heart failure but comparisons are complicated by the deficiency of head‐to‐head trials and differences between patient populations. There are differences in the tolerability profiles; spironolactone is associated with dose‐dependent sexual side effects. Both agents produce dose‐dependent increases in potassium concentrations, although the effect with spironolactone appears to be greater when both agents are administered at recommended doses. Choice of a specific agent should be based on individual patient issues, such as the nature of heart failure and patient concerns about adverse events. CopyrightKeywords
This publication has 32 references indexed in Scilit:
- Nongenomic Effects of Aldosterone in the Human HeartHypertension, 2005
- Aldosterone Nongenomically Worsens Ischemia Via Protein Kinase C-Dependent Pathways in Hypoperfused Canine HeartsHypertension, 2005
- EplerenoneAmerican Journal of Cardiovascular Drugs, 2005
- Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failureAmerican Heart Journal, 2004
- Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic HypertensionHypertension, 2003
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Aldosterone Rapidly Represses Protein Kinase C Activity in Neonatal Rat Cardiomyocytes in VitroEndocrinology, 1997
- Short- and long-term neurohormonal activation following acute myocardial infarctionAmerican Heart Journal, 1993
- Spironolactone and altizide in systemic hypertension: Ambulatory multicenter studyThe American Journal of Cardiology, 1990
- Spironolactone Metabolism: Steady‐State Serum Levels of the Sulfur‐Containing MetabolitesThe Journal of Clinical Pharmacology, 1989